Serum Ngal And Fgf23 May Have Certain Value In Early Diagnosis Of Cin

Aims: This study aimed to assess whether neutrophil gelatinase-associated lipocalin (NGAL) and fibroblast growth factor 23 (FGF23) could be reliable biomarkers for early diagnosis of contrast-induced nephropathy (CIN).Methods: 202 patients who underwent percutaneous coronary intervention (PCI) were included in the research. All subjects were divided into CIN group and non-CIN group. Serum NGAL and FGF23 were evaluated before and 0, 1, and 2 days after PCI. Serum levels of these two markers were compared intra-group and among groups. Receiver-operating characteristic (ROC) analysis and logistic regression models were conducted to assess the diagnostic performance of NGAL and FGF23 in detecting CIN.Results: When compared with baseline values, serum levels of both NGAL and FGF23 in all subjects increased after PCI, and the values peaked 1day after PCI, but the changing was greater in CIN group. There were obvious differences between two groups in serum NGAL after 1, 2 days, and similar differences present in serum FGF23 after 1day. ROC analysis showed that the area under the curve (AUC) of relative values (percent change from the baseline) in NGAL after 1day was 0.899 (95% CI: 0.834-0.964, p=.000), the optimum cutoff was 49% (sensitivity=80%, specificity=92.4%). And the AUC in FGF23 was 0.814 (95% CI: 0.733-0.894, p=.000), the optimum cutoff was 20% (sensitivity=73.3%, specificity=87.6%). Both serum NGAL and serum FGF23 could improve the clinical models in identifying CIN.Conclusions: NGAL and FGF23 may have certain value in early diagnosis of CIN.